We are live on ! Find out more
CGEM icon

Cullinan Oncology

148 hedge funds and large institutions have $490M invested in Cullinan Oncology in 2025 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 44 increasing their positions, 51 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

1% more funds holding

Funds holding: 146148 (+2)

9% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 23

2.1% less ownership

Funds ownership: 112.62%110.53% (-2.1%)

14% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 51

26% less call options, than puts

Call options by funds: $142K | Put options by funds: $193K

39% less capital invested

Capital invested by funds: $799M → $490M (-$309M)

44% less funds holding in top 10

Funds holding in top 10: 95 (-4)

Holders
148
Holders Change
+2
Holders Change %
+1.37%
% of All Funds
1.98%
Holding in Top 10
5
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-44.44%
% of All Funds
0.07%
New
25
Increased
44
Reduced
51
Closed
23
Calls
$142K
Puts
$193K
Net Calls
-$51K
Net Calls Change
+$844K
Name Holding Trade Value Shares
Change
Change in
Stake
Connor, Clark & Lunn Investment Management (CC&L)
51
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$588K +$550K +57,348 +283%
RhumbLine Advisers
52
RhumbLine Advisers
Massachusetts
$540K +$30K +3,130 +5%
TI
53
Trexquant Investment
Connecticut
$518K +$657K +68,467 New
Swiss National Bank
54
Swiss National Bank
Switzerland
$475K
Rafferty Asset Management
55
Rafferty Asset Management
New York
$416K -$333K -34,716 -39%
IIM
56
INTECH Investment Management
Florida
$378K +$174K +18,096 +57%
Invesco
57
Invesco
Georgia
$373K -$98.9K -10,310 -17%
XT
58
XTX Topco
Cayman Islands
$337K +$10.5K +1,094 +3%
JP Morgan Chase
59
JP Morgan Chase
New York
$330K -$1.48M -154,667 -78%
NRD
60
Nebula Research & Development
New York
$329K -$2.83K -295 -0.7%
Legal & General Group
61
Legal & General Group
United Kingdom
$324K
BHCM
62
Brevan Howard Capital Management
Jersey
$307K +$248K +25,864 +176%
NIM
63
NEOS Investment Management
Connecticut
$296K +$103K +10,731 +38%
TE
64
Tema ETFs
New York
$296K +$103K +10,731 +38%
ECM
65
ExodusPoint Capital Management
New York
$266K +$112K +11,700 +50%
Jane Street
66
Jane Street
New York
$260K +$190K +19,813 +136%
Mirae Asset Global ETFs Holdings
67
Mirae Asset Global ETFs Holdings
Hong Kong
$253K +$3.22K +336 +1%
UOC
68
UBS O'Connor
Illinois
$249K -$223K -23,192 -41%
HS
69
HighVista Strategies
Massachusetts
$241K
T. Rowe Price Associates
70
T. Rowe Price Associates
Maryland
$241K +$21.4K +2,228 +8%
D.E. Shaw & Co
71
D.E. Shaw & Co
New York
$238K -$167K -17,438 -36%
MIM
72
MetLife Investment Management
New Jersey
$238K -$5.8K -604 -2%
California State Teachers Retirement System (CalSTRS)
73
California State Teachers Retirement System (CalSTRS)
California
$237K
GCM
74
Graham Capital Management
Connecticut
$223K +$283K +29,505 New
Russell Investments Group
75
Russell Investments Group
United Kingdom
$222K +$282K +29,363 New

CGEM Hedge Fund Activity: Q1 2025 in Review

148 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q1 2025, worth a combined $490M — down 39% from $799M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new CGEM positions and 23 closed out — a net gain of 2 holders — while 44 added to existing stakes and 51 trimmed.

The largest buyer was Lynx1 Capital Management, adding an estimated $18.8M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $12.6M sold.

  • 148 institutional investors held Cullinan Oncology (CGEM) as of Q1 2025, up from 146 in Q4 2024.
  • Funds reported $490M of Cullinan Oncology stock for Q1 2025, down 39% quarter-over-quarter.
  • 25 funds opened new Cullinan Oncology positions in Q1 2025 and 23 closed out, a net change of +2 holders.
  • The largest Cullinan Oncology buyer in Q1 2025 was Lynx1 Capital Management, an estimated $18.8M added.
  • The largest Cullinan Oncology seller in Q1 2025 was Adage Capital Partners, an estimated $12.6M sold.

Based on aggregated 13F filings for Q1 2025.